Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

Background: This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC). Patients and methods: Patients with advanced BC treated with palbociclib from 2017 to 2020 were included. The Kaplan-...

Full description

Saved in:
Bibliographic Details
Main Authors: R.K. Ismail, J. van Breeschoten, M.W.J.M. Wouters, M. van Dartel, S. van der Flier, A.K.L. Reyners, P. de Graeff, A.M.G. Pasmooij, A. de Boer, K.E. Broekman, D.L. Hilarius
Format: article
Language:EN
Published: Elsevier 2021
Subjects:
Palbociclib
Breast cancer
Clinical outcomes
Dose reductions
Older patients
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/8b339da85bf44324a32bf1247266980f
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/8b339da85bf44324a32bf1247266980f

Similar Items